Atossa Therapeutics staples one contingent value right to each common share
ATOS•Atossa Therapeutics will distribute one stapled contingent value right (CVR) for each common share outstanding as of October 19, 2026, or issued thereafter. CVR holders collectively may receive 25% of net proceeds from monetizing the first qualifying FDA priority review voucher, capped at $50 million.
1. CVR distribution terms
Atossa Therapeutics entered a stapled contingent value rights agreement on October 8, 2026. Each CVR will remain attached to its underlying common share and cannot trade separately unless the board elects to detach it.
2. Potential proceeds
Holders collectively will receive 25% of net proceeds from monetizing the first qualifying FDA priority review voucher, subject to a $50 million cap.
